Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hepatitis A vaccine liposomal - Crucell

Drug Profile

Hepatitis A vaccine liposomal - Crucell

Alternative Names: Epaxal; Epaxal Junior; HAVpur; HAVpur Junior; IRIV-hepatitis A vaccine; Virohep-A; Virohep-A Junior

Latest Information Update: 06 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Berna Biotech
  • Developer Crucell; GlaxoSmithKline
  • Class Hepatitis A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis A

Most Recent Events

  • 28 Feb 2011 Crucell completed enrolment in a phase III, long-term follow-up trial for Hepatitis A (Prevention, In infants) in Israel (NCT01307436)
  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
  • 01 Jan 2010 Registered for Hepatitis A in Israel (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top